StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note published on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Up 2.5 %
Shares of GLMD opened at $0.28 on Thursday. The firm has a market cap of $1.39 million, a price-to-earnings ratio of -0.11 and a beta of 0.80. Galmed Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $5.47. The company’s fifty day moving average is $0.37 and its 200-day moving average is $0.37.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last announced its quarterly earnings results on Thursday, May 30th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Further Reading
- Five stocks we like better than Galmed Pharmaceuticals
- Canada Bond Market Holiday: How to Invest and Trade
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 6/24 – 6/28
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
